Skip to main content
All Posts By

admin

marcus-joel-alexandria-real-estate-image

Alexandria Rolls Out Plans for Its RTP Innovation Cluster – Xconomy

By News Archive

marcus-joel-alexandria-real-estate-image

Alexandria Real Estate Equities’ vision to turn a mostly undeveloped property in Research Triangle Park into its latest life science cluster is moving forward with a first phase intended to boost offerings for early-stage startups.

Pasadena, CA-based Alexandria (NYSE: ARE), which operates science and technology campuses across the country, announced the RTP plans today. Alexandria will start by refurbishing an existing building and laying the groundwork for development expected to reach 1 million square feet of space. Those RTP plans put the property shy of similar Alexandria science campuses in San Francisco; Cambridge, MA, and New York. But Alexandria CEO Joel Marcus says each site reflects its market.

Read More
sr-one-logo

The Daily Startup: SR One Launches Startup as Biotech VCs Move Upstream – Venture Capital Dispatch – WSJ

By News Archive

sr-one-logo

Hot biotech startups are attracting increased venture funding, and venture investors are ensuring a slot in the financing of these types of companies by starting the company themselves, Brian Gormley reports for Dow Jones VentureWire. The latest venture firm to do so is SR One, the venture arm of GlaxoSmithKline PLC.GSK.LN +1.16% The group, which invests in medical technologies, has added an entrepreneur in residence to its Cambridge, Mass., offices and has seeded its first startup through the effort, a company formed to develop drugs for cancer and inflammatory diseases. The firm’s launch of its own company comes after 30 years of funding existing companies.

Read More
maryland-israel-showcase-2016-logo

Last chance to register for December 1 MD/Israel Business

By News Archive

maryland-israel-showcase-2016-logo

Tuesday, December 1, 2015 | 5:00 – 7:00 p.m.
The Observation Gallery at Baltimore Washington
International Thurgood Marshall Airport

Meet with over 30 companies and learn about their technology and relationship to Maryland.

Keynote address by Mike Gill, Secretary, Maryland Department of Commerce

Economic Development in Maryland…the Next Chapter
New Addition! Immediately after the Showcase join OurCrowd for an update on The Startup Nation: Israel’s Vibrant Economy.

Read More

178th Edition – November 24, 2015

By BHI Weekly Newsletter Archives

emocha-mobile-health-logo

Amid international growth, emocha gets grant to look at Maryland TB treatment – Technical.ly Baltimore

By News Archive

emocha-mobile-health-logo

emocha Mobile Health received a Small Business Innovation Research grant to further development of its mobile app that provides video-based healthcare observations in some cases where visits were previously required.

The NIH grant, which is for about $200,000 over two years, will allow the Johns Hopkins-based startup to gather data on its miDOT app from Tuberculosis patients in four health departments around the state, said cofounder Morad Elmi. The system is already in use at Baltimore’s health department.

Read More
big-data-pixa

The role of big data in medicine – McKinsey & Company

By News Archive

big-data-pixa

Most companies make a conscious and deliberate decision to embrace digitization and the information revolution. Yet the role of big data in medicine seems almost to compel organizations to become involved. In this interview, Dr. Eric Schadt, the founding director of the Icahn Institute for Genomics and Multiscale Biology at New York’s Mount Sinai Health System, tells McKinsey’s Sastry Chilukuri how data-driven approaches to research can help patients, in what ways technology has the potential to transform medicine and the healthcare system, and how the Icahn Institute is building its talent base. An edited transcript of Schadt’s remarks follows.

Read More
funding-money-invest-pixa

Take a memo, Andreessen Horowitz: 4 areas where it should consider investments – MedCity NewsMedCity News

By News Archive

funding-money-invest-pixa

This week, Andreessen Horowitz said it’s launching a fund dedicated to investments in bioinformatics and “beyond the pill” technology.  The venture capital firm had already gotten its feet wet with investments in these areas, but a dedicated fund is something new and indicates an interest in ramping up its strategy. With its fund, the firm could make a big impact. Here are some insights on some challenges and opportunities in these areas and some companies the firm should consider.

First of all, it’s worth noting some of the health and life science IT companies that Andreessen Horowitz have invested in so far. It’s only a handful to date:

Read More
center-for-innovation-technology-cit-logo

New Center for Innovative Technology CEO Ed Albrigo will take his case for CIT’s worth statewide – Washington Business Journal

By News Archive

center-for-innovation-technology-cit-logo

The new president and chief executive officer of Virginia’s Center for Innovative Technology has roots in high flight and high finance and every intention to bring skills from both sectors to his new job. Ed Albrigo, appointed Nov. 2 by Virginia Gov. Terry McAuliffe to succeed Peter Jobse, who has returned to the private sector after 13 years with the nonprofit CIT, says his goals are lofty — maybe seeding Virginia companies to remotely mine for minerals on the moon and bring them back for use in fusion energy.

Read More
pfizer-logo

Pfizer and Allergan Reach $150 Billion Merger Deal – The New York Times

By News Archive

pfizer-logo

Pfizer has clinched a blockbuster merger with a fellow drug maker, one worth more than $150 billion, that can best be described in superlatives.

When it is announced — most likely on Monday, people briefed on the matter said — the deal to buy Allergan, the maker of Botox, would be one of the biggest ever takeovers in the health care industry. And it would be the largest acquisition yet in a banner year for mergers.

Read More
astrazeneca-logo

AstraZeneca and Sanofi swap 210,000 compounds – The Chemical Engineer

By News Archive

astrazeneca-logo

PHARMACEUTICAL majors AstraZeneca and Sanofi have agreed to swap 210,000 compounds from their proprietary libraries as part of efforts to encourage open innovation in drug development. No money will change hands between the two companies, in what is a relatively new collaborative approach. Both companies will be able to increase the diversity of their compound libraries. AstraZeneca and Sanofi have chosen compounds from each others’ libraries which plug gaps in their own, and will share chemical structures and the procedures to make them.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.